Bristol-Myers Squibb
Projected 2018 sales:
$1.917 billion
2012 sales: $1.019 billion

Sprycel is no Gleevec or Tasigna as far as revenues go, but that's not to say the Bristol-Myers Squibb ($BMY) drug isn't holding its own. The chronic myeloid leukemia treatment reached $287 million in first-quarter sales, up 24% from the same quarter last year and accounting for 7.5% of BMS' first-quarter revenues.

And recently, Sprycel got a boost from the FDA that should help expand sales further. The FDA said in June that it would allow Bristol-Myers to add labeling that includes three-year efficacy and safety data for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase, and 5-year data for the same patients who are resistant or intolerant to Gleevec.

The addition is welcome news for Bristol-Myers, whose patent expiration for bloodthinner Plavix left the company $4.5 billion short in revenues. But the company is facing trouble with Sprycel abroad, including patent-protection issues in India and rejection from NICE in the U.K.

For more:
Bristol-Myers Squibb gets a boost for leukemia drug Sprycel
India to hit Roche, BMS with compulsory licenses on 3 cancer drugs
New Bristol-Myers drug growth cushions plummeting Plavix sales
It's final: Tasigna in, Sprycel out in NICE guidelines


Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.